The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin cancer after five years, new data confirming its prolonged benefit show.

Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, ...

A study led by scientists at NYU Langone Health and its Perlmutter Cancer Center has shown that monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer ...

Studies published in Nature Cancer reveal how bacterial presence in head and neck cancers affects treatment response, potentially opening doors for targeted antibiotic therapies.

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a new study shows. Led by researchers at NYU Langone Health and its Perlmutter Cancer ...